TheraRadar
Data updated: May 26, 2026

THIOLA (tiopronin)

Cystine Disulfide Reduction
Renal Approved 1988-08-11

THIOLA is indicated for the treatment of Cystinuria.

Source: FDA Label • MISSION PHARMA
1
Indication
--
Phase 3 Trials
1
Priority Reviews
37
Years on Market

Details

Status
Prescription
First Approved
1988-08-11
Patent Cliff
2026

Pro Metrics

Patent cliff and revenue data

Unlock with Pro
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: TIOPRONIN

THIOLA Approval History

1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 1988 to 2019
Jun 2019 SUPPL
Label · Labeling
Oct 2001 SUPPL Priority
Mfg · Manufacturing (CMC)
Dec 2000 SUPPL Priority
Mfg · Manufacturing (CMC)

What THIOLA Treats

1 indications

THIOLA is approved for 1 conditions since its original approval in 1988. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Cystinuria
Source: FDA Label

THIOLA Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 3 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to THIOLA

3 of 6

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

DEPEN
PENICILLAMINE
1 shared
Viatris
Shared indications:
Cystinuria
PENICILLAMINE
PENICILLAMINE
1 shared
INVAGEN PHARMS
Shared indications:
Cystinuria
SYPRINE
TRIENTINE HYDROCHLORIDE
1 shared
BAUSCH
Shared indications:
Cystinuria
📋

Clinical Trial Registry

2 trials
Trial Sponsor ID Phase Status Title
NCT01095731 results posted AAAA8597 1R01FD003728-01 Ph 2 completed The Effects of Tiopronin on 3-Aminopropanal Level & Neurologic Outcome After Aneurysmal Subarachnoid Hemorrhage
NCT03663855 results posted 18-00642 Ph 2 completed Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

THIOLA FDA Label Details

Indications & Usage

FDA Label (PDF)

THIOLA is indicated for the treatment of Cystinuria.

THIOLA Patents & Exclusivity

Exclusivity: Jun 2026

Exclusivity

ODE-267 Until Jun 2026
Source: FDA Orange Book

Track THIOLA with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.